MED24

Across TCGA pan-cancer cohorts, MED24 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MED24 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MED24 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED24 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where MED24 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.491	0.765	.004	43	view →
LSCC	DFS	Tertile	II,III,IV	0.949	0.461	<.001	36	view →
PDAC	OS	Median	All	0.403	0.647	<.001	32	view →
LUAD	DFS	Median	All	0.969	0.860	.009	12	view →
CCRCC	DFS	Tertile	All	0.902	0.615	.006	11	view →
GBM	OS	Quartile	All	0.666	0.249	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MED24–HNSC (DFS)

Open the HNSC breakdown →